BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada. Show more

Location: 680 W. Nye Lane, Carson City, NV, 89703, United States | Website: https://bioviepharma.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

12.58M

52 Wk Range

$1.42 - $75.00

Previous Close

$1.67

Open

$1.69

Volume

202,046

Day Range

$1.54 - $1.69

Enterprise Value

-4.537M

Cash

17.54M

Avg Qtr Burn

-4.756M

Insider Ownership

3.28%

Institutional Own.

1.53%

Qtr Updated

06/30/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
BIV201 Details Ascites	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NE3107 Details Alzheimer's disease	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bezisterim (NE3107) Details Early Parkinson's disease Suspected Mover™ Susp. Mover™	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bezisterim (NE3107) Details Neurological symptoms associated with long COVID	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.